➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
Medtronic
Express Scripts
Boehringer Ingelheim

Last Updated: March 1, 2021

DrugPatentWatch Database Preview

Fosaprepitant dimeglumine - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for fosaprepitant dimeglumine and what is the scope of patent protection?

Fosaprepitant dimeglumine is the generic ingredient in two branded drugs marketed by Merck And Co Inc, Accord Hlthcare, Apotex, Baxter Hlthcare Corp, Be Pharms, Dr Reddys, Fresenius Kabi Usa, Lupin Ltd, MSN, Mylan Labs Ltd, Navinta Llc, Qilu, Sandoz Inc, Sungen Pharma, and Teva Pharms Usa, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for fosaprepitant dimeglumine. Nineteen suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for fosaprepitant dimeglumine

See drug prices for fosaprepitant dimeglumine

Recent Clinical Trials for fosaprepitant dimeglumine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
bahria international hospitalPhase 3
University of LahorePhase 3
Prof. Dr. Fridoon Jawad AhmadPhase 3

See all fosaprepitant dimeglumine clinical trials

Generic filers with tentative approvals for FOSAPREPITANT DIMEGLUMINE
Applicant Application No. Strength Dosage Form
  Start Trial  Start TrialUNKNOWNUNKNOWN

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for FOSAPREPITANT DIMEGLUMINE
Tradename Dosage Ingredient NDA Submissiondate
EMEND POWDER;INTRAVENOUS fosaprepitant dimeglumine 022023 2012-01-25

US Patents and Regulatory Information for fosaprepitant dimeglumine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sungen Pharma FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 211624-001 Sep 5, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Sandoz Inc FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 203939-001 Dec 8, 2020 AP RX No No   Start Trial   Start Trial   Start Trial
Qilu FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 213106-001 Sep 8, 2020 AP RX No No   Start Trial   Start Trial   Start Trial
Navinta Llc FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 212957-002 Aug 20, 2020 AP RX No No   Start Trial   Start Trial   Start Trial
Dr Reddys FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 211160-001 Dec 9, 2020 AP RX No No   Start Trial   Start Trial   Start Trial
Apotex FOSAPREPITANT DIMEGLUMINE fosaprepitant dimeglumine POWDER;INTRAVENOUS 205020-001 Sep 5, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for fosaprepitant dimeglumine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Medtronic
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.